Action of uracil analogs on human immunodeficiency virus type 1 and its reverse transcriptase.

AUTOR(ES)

Piras, G

RESUMO

Three structural analogs of 5-ethyl-1-benzyloxymethyl-6-(phenylthio)uracil (E-BPU) inhibited human immunodeficiency virus type 1 (HIV-1) replication without cytotoxicity in vitro and were more potent than azidothymidine and were as potent as E-BPU. The target of these compounds is HIV-1 reverse transcriptase. Reverse transcriptases resistant to nevirapine (tyrosine at position 181 to cysteine) and TIBO R82150 (leucine at position 100 to isoleucine) are cross resistant to E-BPU analogs. Nevirapine- or TIBO R82150-resistant HIV-1 were cross resistant to E-BPU analogs but were inhibited at concentrations 11- to 135-fold lower than the cytotoxic doses.

Documentos Relacionados

• Resistance to nucleoside analogs of selective mutants of human immunodeficiency virus type 2 reverse transcriptase.
• Substrate inhibition of the human immunodeficiency virus type 1 reverse transcriptase.
• RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase.
• PPi analogs as inhibitors of human T-lymphotropic virus type III reverse transcriptase.
• Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase.